These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 30841479)
1. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway. Yao Y; Zhou D; Shi D; Zhang H; Zhan S; Shao X; Sun K; Sun L; Wu G; Tian K; Zhu X; He S Biomed Pharmacother; 2019 Mar; 111():993-1004. PubMed ID: 30841479 [TBL] [Abstract][Full Text] [Related]
2. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway. Huang YK; Kang WM; Ma ZQ; Liu YQ; Zhou L; Yu JC Carcinogenesis; 2019 Apr; 40(2):370-379. PubMed ID: 30371738 [TBL] [Abstract][Full Text] [Related]
3. Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway. Cai C; Dang W; Liu S; Huang L; Li Y; Li G; Yan S; Jiang C; Song X; Hu Y; Gu J Cancer Sci; 2020 Apr; 111(4):1132-1145. PubMed ID: 31977138 [TBL] [Abstract][Full Text] [Related]
4. Letter to editor regarding "GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway". Tang CT; Zeng CY; Chen YX Biomed Pharmacother; 2020 Feb; 122():109792. PubMed ID: 31882307 [No Abstract] [Full Text] [Related]
5. AIM2 inhibits colorectal cancer cell proliferation and migration through suppression of Gli1. Xu M; Wang J; Li H; Zhang Z; Cheng Z Aging (Albany NY); 2020 Dec; 13(1):1017-1031. PubMed ID: 33291082 [TBL] [Abstract][Full Text] [Related]
6. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway. Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766 [TBL] [Abstract][Full Text] [Related]
7. Deregulation of MicroRNA-375 Inhibits Proliferation and Migration in Gastric Cancer in Association With Autophagy-Mediated AKT/mTOR Signaling Pathways. Yuan KT; Li BX; Yuan YJ; Tan M; Tan JF; Dai WG; Feng WD; Zuo JD Technol Cancer Res Treat; 2018 Jan; 17():1533033818806499. PubMed ID: 30355273 [TBL] [Abstract][Full Text] [Related]
8. CSTB Downregulation Promotes Cell Proliferation and Migration and Suppresses Apoptosis in Gastric Cancer SGC-7901 Cell Line. Zhang J; Shi Z; Huang J; Zou X Oncol Res; 2016 Oct; 24(6):487-494. PubMed ID: 28281969 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT-mTOR pathway. Wang J; Cheng Z; Dai D; Li H; Shao X; Xu M Mol Carcinog; 2023 Sep; 62(9):1325-1337. PubMed ID: 37212497 [TBL] [Abstract][Full Text] [Related]
10. Galectin-1 promotes vasculogenic mimicry in gastric adenocarcinoma via the Hedgehog/GLI signaling pathway. You X; Wu J; Wang Y; Liu Q; Cheng Z; Zhao X; Liu G; Huang C; Dai J; Zhou Y; Chen D; Chong Y Aging (Albany NY); 2020 Nov; 12(21):21837-21853. PubMed ID: 33170154 [TBL] [Abstract][Full Text] [Related]
11. Galectin-1 from cancer-associated fibroblasts induces epithelial-mesenchymal transition through β1 integrin-mediated upregulation of Gli1 in gastric cancer. Chong Y; Tang D; Xiong Q; Jiang X; Xu C; Huang Y; Wang J; Zhou H; Shi Y; Wu X; Wang D J Exp Clin Cancer Res; 2016 Nov; 35(1):175. PubMed ID: 27836001 [TBL] [Abstract][Full Text] [Related]
12. NUAK1 activates STAT5/GLI1/SOX2 signaling to enhance cancer cell expansion and drives chemoresistance in gastric cancer. Cao L; Lin G; Fan D; Weng K; Chen Y; Wang J; Li P; Zheng C; Huang C; Xie J Cell Rep; 2024 Jul; 43(7):114446. PubMed ID: 38996065 [TBL] [Abstract][Full Text] [Related]
13. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia. Zhou C; Du J; Zhao L; Liu W; Zhao T; Liang H; Fang P; Zhang K; Zeng H Cell Death Dis; 2021 Mar; 12(3):231. PubMed ID: 33658491 [TBL] [Abstract][Full Text] [Related]
14. GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. Yang Z; Zhang C; Qi W; Cui Y; Xuan Y Exp Cell Res; 2018 Dec; 373(1-2):145-154. PubMed ID: 30321514 [TBL] [Abstract][Full Text] [Related]
15. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway. Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943 [TBL] [Abstract][Full Text] [Related]
16. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines. Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070 [TBL] [Abstract][Full Text] [Related]
17. Sonic Hedgehog-GLI Family Zinc Finger 1 Signaling Pathway Promotes the Growth and Migration of Pancreatic Cancer Cells by Regulating the Transcription of Eukaryotic Translation Initiation Factor 5A2. Xu X; Liu H; Zhang H; Dai W; Guo C; Xie C; Wei S; He S; Xu X Pancreas; 2015 Nov; 44(8):1252-8. PubMed ID: 26465952 [TBL] [Abstract][Full Text] [Related]
18. A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells. Yao H; Sun L; Li J; Zhou X; Li R; Shao R; Zhang Y; Li L Int J Nanomedicine; 2020; 15():7013-7034. PubMed ID: 33061365 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells. Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336 [TBL] [Abstract][Full Text] [Related]
20. HOXB7 overexpression promotes cell proliferation and correlates with poor prognosis in gastric cancer patients by inducing expression of both AKT and MARKs. He X; Liu Z; Xia Y; Xu J; Lv G; Wang L; Ma T; Jiang L; Mou Y; Jiang X; Ma J; Zhao Z; Ni H; Xu W; Ru G; Huang D; Tao H Oncotarget; 2017 Jan; 8(1):1247-1261. PubMed ID: 27901487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]